TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01194882
Drug: Insuplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:
Study: NCT01093183
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04355052
Drug: Hydroxychloroquine in combination of Azithromycin
Normalized name: combinations of barbiturates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
Study: NCT01258296
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mcg/hr transdermal patch
Study: NCT02251197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03887871
Drug: Harnal-D Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harnal-D Tab. 1T single oral administration after meal
Study: NCT04533529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet will be administered orally once daily.
Study: NCT04450836
Drug: Regorafenib then Trifluridine/Tipiracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.
Study: NCT04450836
Drug: Trifluridine/Tipiracil then Regorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.
Study: NCT05014906
Drug: Minocycline 45 MG
Normalized name: minocycline 45 MG
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study: NCT02990364
Drug: EMLA Topical Product
Normalized name: EMLA Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
Study: NCT03953209
Drug: Spironolactone 50Mg Tablet
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
Study: NCT03953209
Drug: Spironolactone 100Mg Tablet
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
Study: NCT03953209
Drug: Spironolactone 200Mg
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
Study: NCT04093466
Drug: CX1003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
Study: NCT02515097
Drug: IDP-122 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical lotion with no active ingredient
Study: NCT04670289
Drug: TenoMiR (Medium Dose)
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mimic of miR29a
Study: NCT03277586
Drug: Probio'Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
Study: NCT03277586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically formulated and packaged inactive substance
Study: NCT02103426
Drug: ASP0113
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT02103426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT04670289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT02189122
Drug: NHP544C 162 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take NHP544C 162 mg once a day for five days.
Study: NCT02189122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take matching placebo for five days.
Study: NCT04026074
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight adapted drug application
Study: NCT04026074
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight adapted drug application
Study: NCT04026074
Drug: Placebo iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration of 0,9% NaCl
Study: NCT02264353
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One piece of placebo before sleep
Study: NCT03194815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the control, or sham, treatment
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg MEDI-546 as a single IV dose
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg MEDI-546 as a single IV dose
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg MEDI-546 as a single IV dose
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg MEDI-546 as a single IV dose
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg/kg MEDI-546 as a single IV dose
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Study: NCT00930683
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.0 mg/kg MEDI-546 as a single IV dose
Study: NCT00051103
Drug: Investigational Cancer Drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025545
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025545
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01134718
Drug: TMC435 (G007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one morning dose of 150 mg
Study: NCT03617458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment with no active ingredients or therapeutic effect.
Study: NCT04340141
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04340141
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03547024
Drug: Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
Study: NCT00263783
Drug: MEDI-522
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
Study: NCT01266499
Drug: both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
Study: NCT01266499
Drug: will not receive PO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: will not receive PO treatment - will receive plecebo treatment
Study: NCT01266499
Drug: PO Garamycin 80mg x 4/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO Garamycin 80mg x 4/d
Study: NCT03274206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLS-ILB-E710c-placebo
Study: NCT02617667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ocular, eye drops
Study: NCT00427245
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01502371
Drug: Placebo Dry Powder Inhaler (DPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DPI, 1 puff QD for 12 weeks
Study: NCT03298347
Drug: 20mg/kg of caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg of caffeine is given to treat AOP
Study: NCT03035890
Drug: Immuno-Therapeutic Agent
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity.
Study: NCT01640080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
Study: NCT04592536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
Study: NCT02774343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
Study: NCT00549419
Drug: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Control group will be assessed using the standard care of traditional vital signs
Study: NCT00549419
Drug: Goal-directed hemodynamic therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Study: NCT00549419
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
Study: NCT03433378
Drug: RETIN-A® (tretinoin) cream, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: RETIN-A® (tretinoin) cream, 0.05%
Study: NCT03433378
Drug: Vehicle of the test product
Normalized name: The Magic Bullet Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of the test product
Study: NCT03074045
Drug: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
Study: NCT02985255
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant Arm
Study: NCT01554371
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02515526
Drug: caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference period
Study: NCT02515526
Drug: ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test period
Study: NCT00002855
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002855
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02196493
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250mg azithromycin three times per week for 12 weeks
Study: NCT02936154
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00642928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day during 4 weeks
Study: NCT00642928
Drug: BF 2.649 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: one BF 2.649 capsule of 5 mg per day during 4 weeks
Study: NCT00642928
Drug: BF 2.649 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One BF 2.649 capsule of 10 mg per day during 4 weeks
Study: NCT00642928
Drug: BF 2.649 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One BF 2.649 capsule of 20 mg per day during 4 weeks
Study: NCT00642928
Drug: BF 2.649 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One BF 2.649 capsule of 40 mg per day during 4 weeks
Study: NCT02682498
Drug: (Bupivacaine Liposome Injectable Suspension)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
Study: NCT04192812
Drug: PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
Study: NCT04192812
Drug: NO GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
Study: NCT04368533
Drug: A standard children's toothpaste containing 1500 ppm fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
Study: NCT03049306
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
Study: NCT00884884
Drug: Double Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily
Study: NCT02600988
Drug: 1000IU/day of Vitamine D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a specified dose of Vitamine D
Study: NCT02600988
Drug: 5000IU/day of Vitamine D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a specified dose of Vitamine D
Study: NCT04160000
Drug: Empiric heart failure drug therapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
Study: NCT01507753
Drug: Omega-3 Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
Study: NCT00642499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04758156
Drug: CleanViewAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1L PEG + ascorbic acid bowel preparation for colonoscopy
Study: NCT04758156
Drug: SUPREP
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulfate solution for colonoscopy bowel preparation
Study: NCT00509925
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Study: NCT00242463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03761407
Drug: 100 mg GRT0151Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule (1 x 100 mg capsule)
Study: NCT03761407
Drug: 125 mg GRT0151Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
Study: NCT00497198
Drug: Placebo of MCI-196 Tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
Study: NCT04915456
Drug: Systemic Steroid (Prednisolone)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
Study: NCT02813447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00312364
Drug: MRE0094
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092365
Drug: MK0966, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003212
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03683914
Drug: Dinoprostone 3Mg Vaginal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
Study: NCT03683914
Drug: placebo vaginal tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
Study: NCT00664456
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
Study: NCT00664456
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
Study: NCT02453087
Drug: DCDS0780A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive escalating doses of DCDS0780A as intravenous infusion.
Study: NCT01702389
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002793
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002793
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00936520
Drug: SAR 1118 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study: NCT00936520
Drug: SAR 1118 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study: NCT00936520
Drug: SAR 1118 5.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study: NCT00872469
Drug: Placebo [Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to active comparator
Study: NCT03249402
Drug: Ethinyl Estradiol + Levonorgestrel
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
Study: NCT02208882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00634322
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV or po given every 6 hours
Study: NCT00113893
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study: NCT00113893
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
Study: NCT03385057
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.